Hangzhou Tigermed
A contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.
Launch date
Employees
Market cap
CAD7.4b
Enterprise valuation
CAD7.5b (Public information from Sep 2024)
Share price
CNY51.41 300347.SZ
小营街道 Zhejiang (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.2b | 5.2b | 7.1b | 7.4b | 7.6b | 9.0b | 10.3b |
| % growth | 14 % | 63 % | 36 % | 4 % | 4 % | 18 % | 15 % |
| EBITDA | 1.3b | 2.1b | 2.4b | 2.6b | 2.4b | 2.9b | 3.4b |
| % EBITDA margin | 40 % | 40 % | 34 % | 36 % | 31 % | 32 % | 33 % |
| Profit | 1.7b | 2.9b | 2.0b | 2.0b | 1.7b | 2.2b | 2.5b |
| % profit margin | 55 % | 55 % | 28 % | 27 % | 23 % | 24 % | 24 % |
| EV / revenue | 40.6x | 18.5x | 11.6x | 5.5x | 4.6x | 3.8x | 3.1x |
| EV / EBITDA | 102.4x | 45.8x | 33.9x | 15.3x | 14.8x | 11.6x | 9.5x |
| R&D budget | 157m | 212m | 235m | 262m | - | - | - |
| R&D % of revenue | 5 % | 4 % | 3 % | 4 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$6.3m | Series A | ||
$2.0m | Early VC | ||
| N/A | N/A | IPO | |
| Total Funding | CAD11.3m | ||
Related Content
Recent News about Hangzhou Tigermed
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
exited
exited
ACQUISITION by Tigermed Oct 2015
ACQUISITION by Hangzhou Tigermed Jul 2024
exited